EP1644411A2 - Stabilised insulin compositions - Google Patents

Stabilised insulin compositions

Info

Publication number
EP1644411A2
EP1644411A2 EP04738978A EP04738978A EP1644411A2 EP 1644411 A2 EP1644411 A2 EP 1644411A2 EP 04738978 A EP04738978 A EP 04738978A EP 04738978 A EP04738978 A EP 04738978A EP 1644411 A2 EP1644411 A2 EP 1644411A2
Authority
EP
European Patent Office
Prior art keywords
human insulin
analogue
lys
thr
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04738978A
Other languages
German (de)
French (fr)
Inventor
Ib Jonassen
Sven Havelund
Thomas B rglund KJELDSEN
Ulla Ribel-Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1644411A2 publication Critical patent/EP1644411A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Definitions

  • the present invention relates to insulin analogues having a fast onset of action.
  • the invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of an insulin analogue having a fast onset of action and insulin having a protracted action.
  • Human insulin is a 51 amino acid peptide hormone consisting of an A-chain and a B-chain having 21 and 30 amino acid residues respectively, interconnected by two cysteine bridges. Insulin may aggregate into hexamers, in which form the hormone is protected from chemical and physical degradation during synthesis and storage. The action of such insulin hexamers is delayed because the hexamers must diffuse and dissociate into dimmers and monomers.
  • Many diabetic patients are treated with multiple daily insulin injections in a regimen comprising one or two daily injections of a protracted insulin to cover the basal requirement supplemented by bolus injections of a rapid acting insulin to cover the requirement related to meals.
  • Protracted insulin compositions are well known in the art.
  • one main type of protracted insulin compositions comprises injectable aqueous suspensions of insulin crystals or amorphous insulin.
  • the insulin compounds utilized typically are protamine insulin, zinc insulin or protamine zinc insulin.
  • Certain drawbacks are associated with the use of insulin suspensions, e.g. the need to suspend the insulin particles by gentle shaking before a defined volume of the suspension is withdrawn from a vial or expelled from a cartridge
  • protracted insulin compositions are solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected.
  • a drawback with these solutions is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the timing of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner.
  • the solid particles of the insulin may act as predictable manner.
  • the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.
  • a further type of protracted insulin compositions is those in which the ⁇ -amino group of residue Lys B29 has been acylated with a long-chain fatty acid, see e.g. WO 95/07931 and WO 98/02460 (Novo Nordisk A/S).
  • One such soluble insulin derivative is B29-N ⁇ -(N-lithocholyl- ⁇ - glutamyl)-des(B30) human insulin.
  • the protracted action has been explained by a reversible binding to albumin in subcutis, blood and peripheral tissue (see e.g. Markussen, Diabetologia 39, 281-288, 1996).
  • Rapid-acting insulin analogues are known, in which a mutation has been introduced with the aim of reducing the tendency to associate into higher molecular weight forms.
  • Examples of such analogues are Asp B28 and Lys B28 Pro B29 human insulin.
  • Some patients use insulin compositions having both a fast onset of action and a more prolonged action. This is effected by using an insulin composition comprising two types of insulin, where one has a fast onset of action and the other a more prolonged action.
  • the two types of insulin may be present in different ratios.
  • Such compositions may be prepared by the patients themselves prior to injection, or more conveniently the composition may be pre-mixed and ready for injection. In such pre-mixed compositions the exchange of insulin monomers between the rapid-acting insulin analogue and the prolonged-action insulin hexamer may take place, which may result in a inferior release profile of insulin.
  • the invention provides analogues of human insulin wherein the amino acid in position B26 is Phe.
  • the remaining amino acid sequence may be identical to that of human insulin or may contain substitutions or deletions.
  • the invention also provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe.
  • the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1, such as between 10:90 and 90:10, e.g. between 30:70 and 70:30.
  • the derivative of human insulin i. may be selected from the group consisting of
  • a pharmaceutical preparation which further comprises a phenolic preservative.
  • Also provided by the invention is a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceu- tical preparation according of the invention, and the use of a preparation of the invention for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
  • insulin As used herein is intended to refer to not only human insulin as such, but also insulin analogues and derivatives. "Human insulin” is well known in the art, and is given below for convenience:
  • analogue of human insulin refers to a polypeptide having the amino acid sequence of human insulin in which one or more amino acids have been deleted and/or replaced by other amino acids, including amino acids not encoded by the genetic code, or comprising additional amino acids, i.e. more than the 51 amino acids of human insulin.
  • derivative of human insulin refers to human insulin or an analogue thereof in which at least one organic substituent is bound to one or more of the amino acids.
  • Non-limiting examples of a “derivative of human insulin” are B29-N ⁇ -myristoyl-des(B30) human insulin, B29-N ⁇ -palmitoyl-des(B30) human insulin, B29-N ⁇ -myristoyl human insulin, B29- N ⁇ -palmitoyl human insulin, B28-N ⁇ -myristoyl Lys B28 Pro 629 human insulin, B28-N ⁇ -palmitoyl Lys B28 Pro 829 human insulin, B30-N ⁇ -myristoyl-Thr B29 Lys B30 human insulin, B30-N ⁇ -palmitoyl- Thr B29 Lys B30 human insulin, B29-N ⁇ -(N-palmitoyl- ⁇ -glutamyl)-des(B
  • chemical stability refers to the tendency of an insulin composition to form stable hexamer structures.
  • the unit "U" corresponds to 6 nmol.
  • treatment means the management and care of a patient for the purpose of combating a disease, disorder or condition.
  • the term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • the present invention relates to rapid-acting analogues of human insulin wherein the amino acid in position B26 is Phe.
  • Such analogues have been found to be particularly useful when used in premixed pharmaceutical preparations where another, long-acting insulin is also present.
  • the monomer insulin molecules of the present invention do not interact with the hexamer formed by the long-acting insulin molecules to the same degree as known fast- acting analogues.
  • the release profile of insulin after injection of the pre-mixed preparation shows an improved release profile, in that both an rapid initial release as well as a continuing, basal release is observed.
  • the invention provides analogues of human insulin wherein the amino acid in position B26 is Phe and wherein the amino acid sequence is at least 80 % identical to that of human insulin.
  • This and the following analogues wherein the amino acid in position B26 is Phe are termed Group A analogues.
  • the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and which has a half life of less than 3 hours measured in the disappearance assay described herein.
  • A-Chain (contd.) 20 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID NO:i; 13 14 15 16 17 18 19
  • B-Chain (contd.) Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe- 13 14 15 16 17 18 19 20 21 22 23 24
  • Xa1 is Phe, Glu or -H
  • Xa2 is Asn or Lys
  • Xa3 is His or Asp
  • Xa4 is Thr or Pro
  • Xa5 is Pro, Thr, Lys, Asp or lie,
  • Xa6 is Lys ,Thr, Pro or Glu
  • Xa7 is Thr, Lys, Pro, Glu or -OH
  • ment Xa5 s Lys In anothe embod ment Xa5 s Lys. In anothe embod ment Xa5 s Asp. In anothe embod ment Xa5 s Thr. In anothe embod ment Xa5 s lie. In anothei embod ment Xa6 s Lys. In another embodiment Xa6 is Thr. In another embodiment Xa6 is Pro. In another embodiment Xa6 is Glu. In another embodiment Xa7 is Thr. In another embodiment Xa7 is Lys. In another embodiment Xa7 is Pro. In another embodiment Xa7 is Glu. In another embodiment Xa7 is -OH.
  • the invention provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe.
  • the invention provides a pharmaceutical preparation wherein the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1.
  • the ratio is between 10:90 and 90:10. In another embodiment the ratio is between 30:70 and 70:30.
  • the invention provides a pharmaceutical preparation wherein the deriva- tive of human insulin i. is selected from the group consisting of
  • the derivative of human insulin i. is B29-N ⁇ -(N-lithocholyl- ⁇ -glutamyl)- des(B30) human insulin.
  • the derivative of human insulin i. is B29-N ⁇ -myristoyl-des(B30) human insulin.
  • the invention provides a pharmaceutical preparation wherein the analogue of human insulin ii. is Des(B1) human insulin or Des(B1) Des(B30) human insulin. In another embodiment the analogue of human insulin ii. is Des(B1) human insulin.
  • the invention provides a pharmaceutical preparation wherein the analogue of human insulin ii. is an analogue selected from Group A analogues.
  • the invention provides a pharmaceutical preparation which further comprises a phenolic preservative.
  • the invention furthermore provides a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation of the invention.
  • the invention provides the use of a preparation of the invention for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
  • the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and wherein the amino acid sequence is at least 80 % identical to that of human insulin.
  • the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and which has a time of disappearance of less than 3 hours measured in the disappearance assay described herein.
  • Xa1 is Phe, Glu or -H
  • Xa2 is Asn or Lys
  • Xa3 is Ala, Asp, Glu, Phe, Gly, lie, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val, Trp, or
  • Xa4 is Thr or Pro
  • Xa5 is Pro, Thr, Lys, Asp or lie
  • Xa6 is Lys ,Thr, Pro or Glu
  • Xa7 is Thr, Lys, Pro, Glu or -OH
  • Xa2 s Lys In one embodiment Xa2 s Lys. In one embodiment Xa3 is Ala, Asp, Glu, Phe, lie, Lys, Leu, Met, Asn, Gin, Arg, Ser, Thr, Val,
  • Trp Trp, or Tyr.
  • Xa3 is Ala, Thr, Ser, Asn or Gin.
  • Xa3 is Ala, Thr, or Ser. In one embodiment Xa3 is Ala.
  • Xa4 is Thr.
  • Xa4 is Lys.
  • Xa5 is Pro, Lys or Asp.
  • Xa5 is Pro. In one embodiment Xa5 is Lys.
  • Xa5 is Asp.
  • Xa5 is Thr.
  • Xa5 is lie.
  • Xa6 is Lys. In one embodiment Xa6 is Thr.
  • Xa6 is Pro
  • Xa6 is Glu
  • Xa7 is Thr.
  • Xa7 is Lys. In one embodiment Xa7 is Pro.
  • Xa7 is Glu
  • Xa7 is -OH.
  • the invention provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe.
  • the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1.
  • the ratio is between 10:90 and 90:10.
  • the ratio is between 30:70 and 70:30.
  • the derivative of human insulin i. is selected from the group consisting of
  • the derivative of human insulin i. is B29-N ⁇ ⁇ (N-lithocholyl- ⁇ -glutamyl)- des(B30) human insulin.
  • the derivative of human insulin i. is B29-N ⁇ -myristoyl-des(B30) human insulin.
  • the analogue of human insulin ii. is Des(B1) human insulin or Des(B1) Des(B30) human insulin.
  • the analogue of human insulin ii. is Des(B1) human insulin. In one embodiment the analogue of human insulin ii. is an analogue according to any one of the embodiments above. In one embodiment the invention provides a pharmaceutical preparation according to any one of the embodiments above which further comprises a phenolic preservative. In one embodiment the invention provides a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation according to any one of the embodiments above. In one embodiment the invention provides the use of a preparation according to any one of the embodiments above for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
  • Insulin preparations of the invention are usually administered from multi-dose containers where a preservative effect is desired.
  • the preservative may be a phenolic molecules.
  • the phenolic molecules in the insulin preparation may be selected from the group consisting of phenol, m-cresol, chloro-cresol, thymol, m-chlor-phenol, resorcinole, 7- hydroxyindole or any mixture thereof.
  • 0.5 to 5.0 mg/ml of phenolic compound may be employed.
  • inventi on 0.6 to 5.0 mg/ml of m-cresol may be employed, In another embodiment of the inventi on 0.5 to 5.0 mg/ml of phenol may be employed, In another embodiment of the inventi on 1.4 to 5.0 mg/ml of phenol may be employed. In another embodiment of the invention 0.5 to 5.0 mg/ml of a mixture of m-cresol or phenol may be employed.
  • the pharmaceutical preparation may further comprise a buffer substance, such as a TRIS, phosphate, glycine or glycylglycine (or another zwitterionic substance) buffer, an isotonicity agent, such as NaCI, glycerol, mannitol and/or lactose
  • a buffer substance such as a TRIS, phosphate, glycine or glycylglycine (or another zwitterionic substance) buffer
  • an isotonicity agent such as NaCI, glycerol, mannitol and/or lactose
  • the pharmaceutical preparation may further comprise physiologically acceptable agents that increase the viscosity of the pharmaceutical preparation.
  • the pharmaceutical preparation according to the invention may furthermore comprise an agent which increases the viscosity, such as polyethylene glycol, polypropylene glycol, copolymers thereof, dextrans and/or polylactides.
  • the insulin preparation of the invention comprises between 0.001 % by weight and 1 % by weight of a non-ionic surfactant, for example tween 20 or Poloxamer 188.
  • a non-ionic surfactant for example tween 20 or Poloxamer 188.
  • the insulin preparation of the present invention may have a pH value in the range of 3.5 to 8.5, more preferably 7.1 to 7.9.
  • the invention furthermore relates to treatment of a patient in which the Group A insulin analogue of the invention and/or a pharmaceutical preparation of the invention, i.e. a preparation comprising both a Group A insulin analogue and a derivative of human insulin such as B29- N ⁇ -(N-lithocholyl- ⁇ -glutamyl)-des(B30) human insulin, is combined with another form of treat- ment.
  • a pharmaceutical preparation of the invention i.e. a preparation comprising both a Group A insulin analogue and a derivative of human insulin such as B29- N ⁇ -(N-lithocholyl- ⁇ -glutamyl)-des(B30) human insulin
  • treatment of a patient with the pharmaceutical preparation of the invention is combined with diet and/or exercise.
  • the pharmaceutical preparation of the invention is administered in combination with one or more further active substances in any suitable ratios.
  • Such further active substances may e.g. be selected from antiobesity agents, antidiabetics, anti- hypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity.
  • the pharmaceutical preparation of the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 adrenergic agonists such as CL- 316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH (melanocyte- stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors such as fluoxetine, seroxat or cita
  • the antiobesity agent is leptin. In another embodiment the antiobesity agent is dexamphetamine or amphetamine. In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine. In still another embodiment the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat.
  • the antiobesity agent is rna ⁇ indol or phentermine. In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.
  • the orally active hypoglycemic agents comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secre- tagogues such as glimepride, ⁇ -glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the ⁇ -cells eg potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 agonists such as those disclosed in
  • the pharmaceutical preparation of the invention is administered in combination with a sulphonylurea e.g. tolbutamide, chlorpropamide, to- lazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.
  • a sulphonylurea e.g. tolbutamide, chlorpropamide, to- lazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.
  • a biguanide e.g. metformin.
  • the pharmaceutical preparation of the invention is administered in combination with a meglitinide eg repaglinide or nateglinide.
  • the pharmaceutical preparation of the invention is administered in combination with a thiazolidinedione insulin sensitizer, e.g. troglitazone, cig ⁇ - tazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr.
  • the pharmaceutical preparation of the invention may be administered in combination with an insulin sensitizer, e.g. such as Gl 262570, YM- 440, MCC-555, JTT-501 , AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, BX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191 , WO 00/63192, WO 00/63193 (Dr.
  • an insulin sensitizer e.g. such as Gl 262570, YM- 440, MCC-555, JTT-501 , AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, BX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/504
  • the pharmaceutical preparation of the invention is administered in combination with an ⁇ -glucosidase inhibitor, e.g. voglibose, emiglitate, migli- tol or acarbose.
  • an ⁇ -glucosidase inhibitor e.g. voglibose, emiglitate, migli- tol or acarbose.
  • the pharmaceutical preparation of the invention is administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells, e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • the pharmaceutical preparation of the invention may be administered in combination with nateglinide.
  • the pharmaceutical preparation of the invention is administered in combination with an antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • an antilipidemic agent e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • the pharmaceutical preparation of the invention is admin- istered in combination with more than one of the above-mentioned compounds, e.g.
  • the pharmaceutical preparation of the invention may be administered in combi- nation with one or more antihypertensive agents.
  • antihypertensive agents examples include ⁇ - blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (an- giotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxa- zosin, urapidil, prazosin and terazosin.
  • the pharmaceutical preparation of the invention may also be combined with NEP inhibitors such as candoxatril.
  • a Group A analogue of this invention is combined with with another form of treat- ment, this administration can be simulataneous or sequential, in a manner effective to result in their combined actions within the subject treated.
  • a Group A analogue may be administered in combination with long-acting derivatives of human insulin as described above, either as a pre-mixed preparation, or by substantially simultaneous adminis- traton of two separate preparations, or by sequential administration, i.e. administrations may be separated in time.
  • the agents would be provided in amounts effective and for periods of time effective to result in their combined presence and their combined actions.
  • the administration of a Group A analogue of the invention may precede, or follow, the other form of treatment by, e.g., intervals ranging from minutes to weeks and months.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, ophthalmiccaly, vaginally or via an implanted reservoir.
  • the pharmaceutical compositions according to the invention may be used for parenteral administration, such as subcutaneous, intramuscular, intrathecal, intravenous, intradermal, intraspinal or intrasternal administration. It will be appreciated that the preferred route of administration will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • Suitable administration forms include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable preparations are also contemplated as being within the scope of the present invention.
  • Suitable administration forms include ophthalmic preparations such as eye drops and eye ointments and topical preparations such as wound dressings.
  • the preparations of the invention are used in connection with insulin pumps.
  • the insulin pumps may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable.
  • Insulin pumps may be skin-mounted or car- ried, and the path of the insulin preparation from the storage compartment of the pump to the patient may be more or less tortuous.
  • Non-lirniting examples of insulin pumps are disclosed in US 5,957,895, US 5,858,001 , US 4,468,221 , US 4,468,221 , US 5,957,895, US 5,858,001 , US 6,074,369, US 5,858,001 , US 5,527,288, and US 6,074,369.
  • preparations of the invention are used in connection with pen-like injection devices, which may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable.
  • pen-like injection devices are FlexPen ® , InnoLet ® , InDuoTM, Innovo ® .
  • preparations of the invention are used in connection with devices for pulmonary administration of aqueous insulin preparations, a non-limiting example of which is the AerX ® device.
  • Rapid-acting analogues of human insulin of the invention were prepared by site-directed mutagenesis as described in Brange et al., Nature vol 333 page 679 - 682 (1988).
  • Derivatives of human insulin having a protracted action were made by acylation of biosyn- thetic des(B30) human insulin in position Lys B29 N e by tetradecanoic acid and a series of cholic acid derivatives using conventional peptide chemistry as described in WO 99/21888.
  • Insulin and insulin analogues for pharmacokinetic experiments were prepared as preparations containing 600 nmol of insulin per ml and 2 - 2.5 Zn 2+ per hexamer, 1,5 % glycerol and 0.3% phenol.
  • Insulin preparations for pharmacokinetic experiments were labelled by 65 Zn 2+ or by iodinationation of Tyr ⁇ 14 of the appropriate analogues by 125 l 2 (see Jorgensen.KH, Lar- sen.UD: Homogeneous mono-125l-insulins. Preparation and characterization of Mono-1251- (Tyr A14)- and Mono-125l-(Tyr A19)-insulin. DIABETOLOGIA 19:546-554, 1980) and NHP insulin was labelled by Tyr A14 ( 125 l-human insulin).
  • Formulated preparations of insulin analogues labelled in position Tyr A14 by 125 l or by 65 Zn 2+ were injected subcutaneously in pigs as previously described (Ribel, U., J ⁇ rgensen, K, Brange, J, and Henriksen, U. : The pig as a model for subcutaneous insulin absorption in man. Serrano-Rios, M and Lefebvre, P. J. 891-896. 1985. Amsterdam; New York;Qxford, Elsevier Science Publishers. 1985). The disappearance of the radioactive label from the site of subcutaneous injection was monitored using a modification of the traditional external gamma-counting method (Ribel, U.: Subcutaneous absorption of insulin analogues.
  • Analogue 1 B10Asp B26Phe DesB30 human insulin.
  • Analogue 2 B10Asp B26Phe B28Asp DesB30 human insulin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 is substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of an insulin analogue having a fast onset of action and insulin having a protracted action.

Description

STABILISED INSULIN COMPOSITIONS
FIELD OF THE INVENTION
The present invention relates to insulin analogues having a fast onset of action. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of an insulin analogue having a fast onset of action and insulin having a protracted action.
BACKGROUND OF THE INVENTION
Human insulin is a 51 amino acid peptide hormone consisting of an A-chain and a B-chain having 21 and 30 amino acid residues respectively, interconnected by two cysteine bridges. Insulin may aggregate into hexamers, in which form the hormone is protected from chemical and physical degradation during synthesis and storage. The action of such insulin hexamers is delayed because the hexamers must diffuse and dissociate into dimmers and monomers.
Many diabetic patients are treated with multiple daily insulin injections in a regimen comprising one or two daily injections of a protracted insulin to cover the basal requirement supplemented by bolus injections of a rapid acting insulin to cover the requirement related to meals.
Protracted insulin compositions are well known in the art. Thus, one main type of protracted insulin compositions comprises injectable aqueous suspensions of insulin crystals or amorphous insulin. In these compositions, the insulin compounds utilized typically are protamine insulin, zinc insulin or protamine zinc insulin. Certain drawbacks are associated with the use of insulin suspensions, e.g. the need to suspend the insulin particles by gentle shaking before a defined volume of the suspension is withdrawn from a vial or expelled from a cartridge
Another type of protracted insulin compositions are solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected. A drawback with these solutions is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the timing of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner. A further drawback is that the solid particles of the insulin may act as predictable manner. A further drawback is that the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.
A further type of protracted insulin compositions is those in which the ε-amino group of residue LysB29 has been acylated with a long-chain fatty acid, see e.g. WO 95/07931 and WO 98/02460 (Novo Nordisk A/S). One such soluble insulin derivative is B29-Nε-(N-lithocholyl-γ- glutamyl)-des(B30) human insulin. The protracted action has been explained by a reversible binding to albumin in subcutis, blood and peripheral tissue (see e.g. Markussen, Diabetologia 39, 281-288, 1996).
Rapid-acting insulin analogues are known, in which a mutation has been introduced with the aim of reducing the tendency to associate into higher molecular weight forms. Examples of such analogues are AspB28 and LysB28ProB29 human insulin.
Some patients use insulin compositions having both a fast onset of action and a more prolonged action. This is effected by using an insulin composition comprising two types of insulin, where one has a fast onset of action and the other a more prolonged action. The two types of insulin may be present in different ratios. Such compositions may be prepared by the patients themselves prior to injection, or more conveniently the composition may be pre-mixed and ready for injection. In such pre-mixed compositions the exchange of insulin monomers between the rapid-acting insulin analogue and the prolonged-action insulin hexamer may take place, which may result in a inferior release profile of insulin.
There is thus a need for insulin analogues suitable for pre-mixed compositions which retain the action profiles of both insulin components.
SUMMARY OF THE INVENTION
The invention provides analogues of human insulin wherein the amino acid in position B26 is Phe. The remaining amino acid sequence may be identical to that of human insulin or may contain substitutions or deletions. The invention also provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe. Also provided by the invention is a pharmaceutical preparation wherein the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1, such as between 10:90 and 90:10, e.g. between 30:70 and 70:30. The derivative of human insulin i. may be selected from the group consisting of
B29-Nε-myristoyl-des(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε- myristoyl human insulin, B29-Nε-palmitoyl human insulin, B28-Nε-myristoyl LysB28 Pro629 human insulin, B28-Nε-palmitoyl LysB28 ProB29 human insulin, B30-Nε-myristoyl-ThrB29LysB30 human insulin, B30-Nε-palmitoyl-ThrB29LysB3° human insulin, B29-Nε-(N-palmitoyl-γ-glutamyl)- des(B30) human insulin, B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-Nε- (ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-Nε-(ω-carboxyheptadecanoyl) human insulin, such as B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, e.g. B29- Nε-myristoyl-des(B30) human insulin. The rapid acting component ii. may be Des(B1) human insulin or Des(B1) Des(B30) human insulin, such as Des(B1) human insulin.
Also provided by the invention is a pharmaceutical preparation which further comprises a phenolic preservative.
Also provided by the invention is a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceu- tical preparation according of the invention, and the use of a preparation of the invention for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
DEFINITIONS
Unless otherwise specified, the term "insulin" as used herein is intended to refer to not only human insulin as such, but also insulin analogues and derivatives. "Human insulin" is well known in the art, and is given below for convenience:
Human Insulin :
A-C ain | 7 | Gly-Ile-Val-Glu-Gln-Cys-Cys-T r-Ser-Ile-Cys-Ser- 1 2 3 4 5 β | 8 9 10 11 12 S B-Chain Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val- 1 2 3 4 5 6 7 8 9 10 11 12
A-Chain (contd.) 20 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn 13 14 15 16 17 18 19 | 21 —S B-Chain (contd.) I Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe- 13 14 15 16 17 18 19 20 21 22 23 24
B-Chain (contd.) P e-Tyr-Thr-Pro-Lys-Thr 25 26 27 28 29 30
The term "analogue of human insulin" as used herein refers to a polypeptide having the amino acid sequence of human insulin in which one or more amino acids have been deleted and/or replaced by other amino acids, including amino acids not encoded by the genetic code, or comprising additional amino acids, i.e. more than the 51 amino acids of human insulin.
The term "derivative of human insulin" as used herein refers to human insulin or an analogue thereof in which at least one organic substituent is bound to one or more of the amino acids. Non-limiting examples of a "derivative of human insulin" are B29-Nε-myristoyl-des(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε-myristoyl human insulin, B29- Nε-palmitoyl human insulin, B28-Nε-myristoyl LysB28 Pro629 human insulin, B28-Nε-palmitoyl LysB28 Pro829 human insulin, B30-Nε-myristoyl-ThrB29LysB30 human insulin, B30-Nε-palmitoyl- ThrB29LysB30 human insulin, B29-Nε-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-Nε- (N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-Nε-(ω-carboxyheptadecanoyl)- des(B30) human insulin and B29-Nε-(ω-carboxyheptadecanoyl) human insulin
The term "chemical stability" as used herein refers to the tendency of an insulin composition to form stable hexamer structures.
In the present context, the unit "U" corresponds to 6 nmol.
The terms "treatment" and "treating" as used herein means the management and care of a patient for the purpose of combating a disease, disorder or condition. The term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition. The patient to be treated is preferably a mammal, in particular a human being.
The three letter codes and one letter codes for the amino acid residues used herein are those stated in J. Biol. Chem. 243, p. 3558 (1968).
DESCRIPTION OF THE INVENTION
The present invention relates to rapid-acting analogues of human insulin wherein the amino acid in position B26 is Phe. Such analogues have been found to be particularly useful when used in premixed pharmaceutical preparations where another, long-acting insulin is also present. The monomer insulin molecules of the present invention do not interact with the hexamer formed by the long-acting insulin molecules to the same degree as known fast- acting analogues. As a result, the release profile of insulin after injection of the pre-mixed preparation shows an improved release profile, in that both an rapid initial release as well as a continuing, basal release is observed.
In one embodiment the invention provides analogues of human insulin wherein the amino acid in position B26 is Phe and wherein the amino acid sequence is at least 80 % identical to that of human insulin. This and the following analogues wherein the amino acid in position B26 is Phe are termed Group A analogues.
In another embodiment the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and which has a half life of less than 3 hours measured in the disappearance assay described herein.
In another embodiment the invention provides an analogue of human insulin having the sequence
A-Chain S S I 7 | Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser- 1 2 3 4 5 6 | 8 9 10 11 12 S I B-Chain S I Xal-Val-Xa2-Gln-His-Leu-Cys-Gly-Ser-Xa3-Leu-Val- 1 2 3 4 5 6 7 8 9 10 11 12
A-Chain (contd.) 20 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID NO:i; 13 14 15 16 17 18 19 | 21 i S B-Chain (contd.) Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe- 13 14 15 16 17 18 19 20 21 22 23 24
B-Chain (contd.
Phe-Phe-Xa4-Xa5-Xa6-Xa7 ( SEQ ID NO : 2 ) 25 26 27 28 29 30
wherein Xa1 is Phe, Glu or -H,
Xa2 is Asn or Lys,
Xa3 is His or Asp,
Xa4 is Thr or Pro,
Xa5 is Pro, Thr, Lys, Asp or lie,
Xa6 is Lys ,Thr, Pro or Glu,
Xa7 is Thr, Lys, Pro, Glu or -OH,
In anothe; embod ment Xa1 s Phe. In anothei embod ment Xa1 s Glu. In anothe embod ment Xa1 s -H. In anothe embod ment Xa2 s Asn. In anothei embod ment Xa2 s Lys. In anothei embod: ment Xa3 s His. In anothei embod ment Xa3 s Asp. In anothei embod ment Xa4 s Thr. In anothei embod ment Xa4 s Lys. In anothe embod ment Xa5 s Pro, Lys or In anothei embod ment Xa5 s Pro. In anothe embod ment Xa5 s Lys. In anothe embod ment Xa5 s Asp. In anothe embod ment Xa5 s Thr. In anothe embod ment Xa5 s lie. In anothei embod ment Xa6 s Lys. In another embodiment Xa6 is Thr. In another embodiment Xa6 is Pro. In another embodiment Xa6 is Glu. In another embodiment Xa7 is Thr. In another embodiment Xa7 is Lys. In another embodiment Xa7 is Pro. In another embodiment Xa7 is Glu. In another embodiment Xa7 is -OH.
The situation where Xa1 is -H corresponds to deletion of the amino acid in position B1. Simi- larly, the situation where Xa7 is -OH corresponds to deletion of the amino acid in position B30.
In another embodiment the invention provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe. In one embodiment the invention provides a pharmaceutical preparation wherein the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1.
In another embodiment the ratio is between 10:90 and 90:10. In another embodiment the ratio is between 30:70 and 70:30. In one embodiment the invention provides a pharmaceutical preparation wherein the deriva- tive of human insulin i. is selected from the group consisting of
B29-Nε-myristoyl-des(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε- myristoyl human insulin, B29-Nc-palmitoyl human insulin, B28-Nε-myristoyl LysB28 Pro629 human insulin, B28-Nε-palmitoyl LysB28 Pro829 human insulin, B30-Nc-myristoyl-ThrB29LysB30 human insulin, B30-Nε-palmitoyl-ThrB29LysB30 human insulin, B29-Nε-(N-palmitoyl-γ-glutarnyl)- des(B30) human insulin, B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-Nε- (ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-Nε-(ω-carboxyheptadecanoyl) human insulin.
In another embodiment the derivative of human insulin i. is B29-Nε-(N-lithocholyl-γ-glutamyl)- des(B30) human insulin. In another embodiment the derivative of human insulin i. is B29-Nε-myristoyl-des(B30) human insulin.
In one embodiment the invention provides a pharmaceutical preparation wherein the analogue of human insulin ii. is Des(B1) human insulin or Des(B1) Des(B30) human insulin. In another embodiment the analogue of human insulin ii. is Des(B1) human insulin.
In one embodiment the invention provides a pharmaceutical preparation wherein the analogue of human insulin ii. is an analogue selected from Group A analogues. In one embodiment the invention provides a pharmaceutical preparation which further comprises a phenolic preservative. The invention furthermore provides a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation of the invention.
In another embodiment the invention provides the use of a preparation of the invention for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
In another aspect the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and wherein the amino acid sequence is at least 80 % identical to that of human insulin. In one embodiment the invention provides an analogue of human insulin wherein the amino acid in position B26 is Phe and which has a time of disappearance of less than 3 hours measured in the disappearance assay described herein.
In one embodiment the invention provides an analogue of human insulin having the sequence
A-Chain I 7 | Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser- 1 2 3 4 5 6 | 8 9 10 11 12 S I B-Chain S I Xal-Val-Xa2-Gln-His-Leu-Cys-Gly-Ser-Xa3-Leu-Val- 1 2 3 4 5 6 7 8 9 10 11 12 A-Chain (contd.) 20 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID NO:l) 13 14 15 16 17 18 19 | 21 i s
B-Chain (contd.) S I Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe- 13 14 15 16 17 18 19 20 21 22 23 24
B-Chain (contd.)
Phe-Phe-Xa4-Xa5-Xa6-Xa7 (SEQ ID NO:2) 25 26 27 28 29 30
wherein Xa1 is Phe, Glu or -H,
Xa2 is Asn or Lys,
Xa3 is Ala, Asp, Glu, Phe, Gly, lie, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val, Trp, or
Tyr,
Xa4 is Thr or Pro, Xa5 is Pro, Thr, Lys, Asp or lie,
Xa6 is Lys ,Thr, Pro or Glu,
Xa7 is Thr, Lys, Pro, Glu or -OH,
In one embodiment Xa1 s Phe or -H
In one embodiment Xa1 s Phe.
In one embodiment Xa1 s Glu.
In one embodiment Xa1 s -H.
In one embodiment Xa2 s Asn.
In one embodiment Xa2 s Lys. In one embodiment Xa3 is Ala, Asp, Glu, Phe, lie, Lys, Leu, Met, Asn, Gin, Arg, Ser, Thr, Val,
Trp, or Tyr.
In one embodiment Xa3 is Ala, Thr, Ser, Asn or Gin.
In one embodiment Xa3 is Ala, Thr, or Ser. In one embodiment Xa3 is Ala.
In one embodiment Xa4 is Thr.
In one embodiment Xa4 is Lys.
In one embodiment Xa5 is Pro, Lys or Asp.
In one embodiment Xa5 is Pro. In one embodiment Xa5 is Lys.
In one embodiment Xa5 is Asp.
In one embodiment Xa5 is Thr.
In one embodiment Xa5 is lie.
In one embodiment Xa6 is Lys. In one embodiment Xa6 is Thr.
In one embodiment Xa6 is Pro.
In one embodiment Xa6 is Glu.
In one embodiment Xa7 is Thr.
In one embodiment Xa7 is Lys. In one embodiment Xa7 is Pro.
In one embodiment Xa7 is Glu.
In one embodiment Xa7 is -OH.
In one embodiment the invention provides a pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe.
In one embodiment the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1.
In one embodiment the ratio is between 10:90 and 90:10.
In one embodiment the ratio is between 30:70 and 70:30.
In one embodiment the derivative of human insulin i. is selected from the group consisting of
B29-Nε-myristoyl-dβs(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε- myristoyl human insulin, B29-Nε~palmitoyl human insulin, B28-Nε-myristoyl LysB28 Pro629 hu- man insulin, B28-Nε-palmitoyl LysB28 Pro829 human insulin, B30-Nε-myristoyl-ThrB29Lys830 human insulin, B30-Nε-palmitoyl-ThrB29Lys830 human insulin, B29-Nε-(N-palmitoyl-γ-glutamyl)- des(B30) human insulin, B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-Nε- (ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-Nε-(ω-carboxyheptadecanoyl) human insulin.
In one embodiment the derivative of human insulin i. is B29-Nε~(N-lithocholyl-γ-glutamyl)- des(B30) human insulin.
In one embodiment the derivative of human insulin i. is B29-Nε-myristoyl-des(B30) human insulin. In one embodiment the analogue of human insulin ii. is Des(B1) human insulin or Des(B1) Des(B30) human insulin.
In one embodiment the analogue of human insulin ii. is Des(B1) human insulin. In one embodiment the analogue of human insulin ii. is an analogue according to any one of the embodiments above. In one embodiment the invention provides a pharmaceutical preparation according to any one of the embodiments above which further comprises a phenolic preservative. In one embodiment the invention provides a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation according to any one of the embodiments above. In one embodiment the invention provides the use of a preparation according to any one of the embodiments above for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
PHARMACEUTICAL COMPOSITIONS
Insulin preparations of the invention are usually administered from multi-dose containers where a preservative effect is desired. In one embodiment the preservative may be a phenolic molecules. The phenolic molecules in the insulin preparation may be selected from the group consisting of phenol, m-cresol, chloro-cresol, thymol, m-chlor-phenol, resorcinole, 7- hydroxyindole or any mixture thereof.
In one embodiment of the invention 0.5 to 5.0 mg/ml of phenolic compound may be employed.
In another embodiment of the inventi on 0.6 to 5.0 mg/ml of m-cresol may be employed, In another embodiment of the inventi on 0.5 to 5.0 mg/ml of phenol may be employed, In another embodiment of the inventi on 1.4 to 5.0 mg/ml of phenol may be employed. In another embodiment of the invention 0.5 to 5.0 mg/ml of a mixture of m-cresol or phenol may be employed.
In another embodiment of the invention 1.4 to 5.0 mg/ml of a mixture of m-cresol or phenol may be employed. The pharmaceutical preparation may further comprise a buffer substance, such as a TRIS, phosphate, glycine or glycylglycine (or another zwitterionic substance) buffer, an isotonicity agent, such as NaCI, glycerol, mannitol and/or lactose
The pharmaceutical preparation may further comprise physiologically acceptable agents that increase the viscosity of the pharmaceutical preparation. Thus, the pharmaceutical preparation according to the invention may furthermore comprise an agent which increases the viscosity, such as polyethylene glycol, polypropylene glycol, copolymers thereof, dextrans and/or polylactides.
In a particular embodiment the insulin preparation of the invention comprises between 0.001 % by weight and 1 % by weight of a non-ionic surfactant, for example tween 20 or Poloxamer 188.
The insulin preparation of the present invention may have a pH value in the range of 3.5 to 8.5, more preferably 7.1 to 7.9.
COMBINATION TREATMENT
The invention furthermore relates to treatment of a patient in which the Group A insulin analogue of the invention and/or a pharmaceutical preparation of the invention, i.e. a preparation comprising both a Group A insulin analogue and a derivative of human insulin such as B29- Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, is combined with another form of treat- ment.
In one aspect of the invention, treatment of a patient with the pharmaceutical preparation of the invention is combined with diet and/or exercise.
In another aspect of the invention the pharmaceutical preparation of the invention is administered in combination with one or more further active substances in any suitable ratios. Such further active substances may e.g. be selected from antiobesity agents, antidiabetics, anti- hypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity. Thus, in a further aspect of the invention the pharmaceutical preparation of the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 adrenergic agonists such as CL- 316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH (melanocyte- stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors such as fluoxetine, seroxat or cita- lopram, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth factors such as prolactin or placental lactogen, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator-activated receptor) modulators, RXR (retinoid X receptor) modulators, TR β agonists, AGRP (Agouti related protein) inhibitors, H3 histamine antagonists, opioid antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotro- phic factor.
In one embodiment of the invention the antiobesity agent is leptin. In another embodiment the antiobesity agent is dexamphetamine or amphetamine. In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine. In still another embodiment the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat.
In another embodiment the antiobesity agent is rna∑indol or phentermine. In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.
The orally active hypoglycemic agents comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secre- tagogues such as glimepride, α-glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the β-cells eg potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 agonists such as those disclosed in WO 00/42026 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, DPP- IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenoly- sis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antilipidemic agents, compounds lowering food intake, PPAR (peroxisome proliferator-activated receptor) and RXR (retinoid X receptor) ago- nists, such as ALRT-268, LG-1268 or LG-1069.
In a further embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a sulphonylurea e.g. tolbutamide, chlorpropamide, to- lazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide. In another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a biguanide, e.g. metformin.
In yet another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a meglitinide eg repaglinide or nateglinide. In still another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a thiazolidinedione insulin sensitizer, e.g. troglitazone, cigϋ- tazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference. In still another embodiment of the invention the pharmaceutical preparation of the invention may be administered in combination with an insulin sensitizer, e.g. such as Gl 262570, YM- 440, MCC-555, JTT-501 , AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, BX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191 , WO 00/63192, WO 00/63193 (Dr. Reddy's Research Foundation) and WO 00/23425, WO 00/23415, WO 00/23451 , WO 00/23445, WO 00/23417, WO 00/23416, WO 00/63153, WO 00/63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo Nordisk A/S), which are incorporated herein by reference. In a further embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an α-glucosidase inhibitor, e.g. voglibose, emiglitate, migli- tol or acarbose. In another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells, e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide. In yet another embodiment of the invention the pharmaceutical preparation of the invention may be administered in combination with nateglinide.
In still another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine. In another aspect of the invention, the pharmaceutical preparation of the invention is admin- istered in combination with more than one of the above-mentioned compounds, e.g. in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acar- bose; nateglinide and metformin; acarbose and metformin; a sulphonylurea, metformin and troglitazone; metformin and a sulphonylurea; etc. Furthermore, the pharmaceutical preparation of the invention may be administered in combi- nation with one or more antihypertensive agents. Examples of antihypertensive agents are β- blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (an- giotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxa- zosin, urapidil, prazosin and terazosin. The pharmaceutical preparation of the invention may also be combined with NEP inhibitors such as candoxatril.
Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. It should be understood that any suitable combination of the compounds according to the in- vention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention.
Whenever a Group A analogue of this invention is combined with with another form of treat- ment, this administration can be simulataneous or sequential, in a manner effective to result in their combined actions within the subject treated. In one embodiment, a Group A analogue may be administered in combination with long-acting derivatives of human insulin as described above, either as a pre-mixed preparation, or by substantially simultaneous adminis- traton of two separate preparations, or by sequential administration, i.e. administrations may be separated in time. The agents would be provided in amounts effective and for periods of time effective to result in their combined presence and their combined actions. The administration of a Group A analogue of the invention may precede, or follow, the other form of treatment by, e.g., intervals ranging from minutes to weeks and months.
The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, ophthalmiccaly, vaginally or via an implanted reservoir. In one embodiment, the pharmaceutical compositions according to the invention may be used for parenteral administration, such as subcutaneous, intramuscular, intrathecal, intravenous, intradermal, intraspinal or intrasternal administration. It will be appreciated that the preferred route of administration will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen. Suitable administration forms include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable preparations are also contemplated as being within the scope of the present invention.
Other suitable administration forms include ophthalmic preparations such as eye drops and eye ointments and topical preparations such as wound dressings.
In one embodiment the preparations of the invention are used in connection with insulin pumps. The insulin pumps may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable. Insulin pumps may be skin-mounted or car- ried, and the path of the insulin preparation from the storage compartment of the pump to the patient may be more or less tortuous. Non-lirniting examples of insulin pumps are disclosed in US 5,957,895, US 5,858,001 , US 4,468,221 , US 4,468,221 , US 5,957,895, US 5,858,001 , US 6,074,369, US 5,858,001 , US 5,527,288, and US 6,074,369.
In another embodiment the preparations of the invention are used in connection with pen-like injection devices, which may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable. Non-limiting examples of pen-like injection devices are FlexPen®, InnoLet®, InDuo™, Innovo®. In a further embodiment preparations of the invention are used in connection with devices for pulmonary administration of aqueous insulin preparations, a non-limiting example of which is the AerX® device.
EXAMPLES
Disappearance assay
Rapid-acting analogues of human insulin of the invention were prepared by site-directed mutagenesis as described in Brange et al., Nature vol 333 page 679 - 682 (1988).
Derivatives of human insulin having a protracted action were made by acylation of biosyn- thetic des(B30) human insulin in position LysB29Ne by tetradecanoic acid and a series of cholic acid derivatives using conventional peptide chemistry as described in WO 99/21888.
Insulin and insulin analogues for pharmacokinetic experiments were prepared as preparations containing 600 nmol of insulin per ml and 2 - 2.5 Zn2+ per hexamer, 1,5 % glycerol and 0.3% phenol. Insulin preparations for pharmacokinetic experiments were labelled by 65Zn2+ or by iodinationation of Tyr^14 of the appropriate analogues by 125l2 (see Jorgensen.KH, Lar- sen.UD: Homogeneous mono-125l-insulins. Preparation and characterization of Mono-1251- (Tyr A14)- and Mono-125l-(Tyr A19)-insulin. DIABETOLOGIA 19:546-554, 1980) and NHP insulin was labelled by TyrA14(125l-human insulin).
Formulated preparations of insulin analogues labelled in position TyrA14 by 125l or by 65Zn2+ were injected subcutaneously in pigs as previously described (Ribel, U., Jørgensen, K, Brange, J, and Henriksen, U. : The pig as a model for subcutaneous insulin absorption in man. Serrano-Rios, M and Lefebvre, P. J. 891-896. 1985. Amsterdam; New York;Qxford, Elsevier Science Publishers. 1985). The disappearance of the radioactive label from the site of subcutaneous injection was monitored using a modification of the traditional external gamma-counting method (Ribel, U.: Subcutaneous absorption of insulin analogues. Berger, M. and Gries, F. A. 70-77. 1993. Stuttgart; New York, Georg Thime Verlag). With this modified method it was possible to measure continuously the disappearance of radioactivity from a subcutaneous depot for several days using cordless portable device (Scancys Laborato- rieteknik, Veerløse, DK-3500). The measurements were performed at 1-min intervals, and the counting values were corrected for background activity. An insulin dose of 60 nmol (equal to 10 units of human insulin) was used and each pig received both a test analogue and tet- radecanoyl des(B30) human insulin in separate depots. Results are reported as the half-life of the insulin species in the subcutaneous depot, i.e. as the time measured to reduce the radioactivity to one half of the initial level.
The following insulin analogues were tested in a preparation also containing protracted insulin B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin (in the following table termed Protlns) in the amounts indicated in the table below:
Analogue 1 : B10Asp B26Phe DesB30 human insulin. Analogue 2: B10Asp B26Phe B28Asp DesB30 human insulin.
For comparison B28Asp human insulin was tested.

Claims

1. An analogue of human insulin wherein the amino acid in position B26 is Phe and wherein the amino acid sequence is at least 80 % identical to that of human insulin.
2. An analogue of human insulin wherein the amino acid in position B26 is Phe and which has a time of disappearance of less than 3 hours measured in the disappearance assay described herein.
3. An analogue of human insulin having the sequence
A-Chain I 7 | Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser- 1 2 3 4 5 6 | 8 9 10 11 12 S I B-Chain S I Xal-Val-Xa2-Gln-His-Leu-Cys-Gly-Ser-Xa3-Leu-Val- 1 2 3 4 5 6 7 8 9 10 11 12
A-Chain (contd.) 20 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID NO:l) 13 14 15 16 17 18 19 | 21 I S I B-Chain (contd.) S I Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe- 13 14 15 16 17 18 19 20 21 22 23 24
B-Chain (contd.) Phe-Phe-Xa4-Xa5-Xa6-Xa7 ( SEQ ID NO : 2 ) 25 26 27 28 29 30
wherein Xa1 is Phe, Glu or -H, Xa2 is Asn or Lys,
Xa3 is Ala, Asp, Glu, Phe, Gly, lie, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val, Trp, or Tyr,
Xa4 is Thr or Pro, Xa5 is Pro, Thr, Lys, Asp or lie, Xa6 is Lys ,Thr, Pro or Glu,
Xa7 is Thr, Lys, Pro, Glu or -OH,
4. An analogue of human insulin according to claim 3 wherein Xa1 is Phe or -H.
5. An analogue of human insulin according to claim 4 wherein Xa1 is Phe.
6. An analogue of human insulin according to claim 3 wherein Xa1 is Glu.
7. An analogue of human insulin according to claim 4 wherein Xa1 is -H.
8. An analogue of human insulin according to any one of the claims 3 to 7 wherein Xa2 is Asn.
9. An analogue of human insulin according to any one of the claims 3 to 7 wherein Xa2 is Lys.
10. An analogue of human insulin according to any one of the claims 3 to 9 wherein Xa3 is Ala, Asp, Glu, Phe, lie, Lys, Leu, Met, Asn, Gin, Arg, Ser, Thr, Val, Trp, or Tyr.
11. An analogue of human insulin according to claim 10 wherein Xa3 is Ala, Thr, Ser, Asn or Gin.
12. An analogue of human insulin according to claim 11 wherein Xa3 is Ala, Thr, or Ser.
13. An analogue of human insulin according to any one of the claims 3 to 9 wherein Xa3 is Ala.
14. An analogue of human insulin according to any one of the claims 3 to 13 wherein Xa4 is Thr.
15. An analogue of human insulin according to any one of the claims 3 to 13 wherein Xa4 is Lys.
16. An analogue of human insulin according to any one of the claims 3 to 15 wherein Xa5 is Pro, Lys or Asp.
17. An analogue of human insulin according to claim 16 wherein Xa5 is Pro.
18. An analogue of human insulin according to claim 16 wherein Xa5 is Lys.
19. An analogue of human insulin according to claim 16 wherein Xa5 is Asp.
20. An analogue of human insulin according to any one of the claims 3 to 15 wherein Xa5 is Thr.
21. An analogue of human insulin according to any one of the claims 3 to 15 wherein Xa5 is lie.
22. An analogue of human insulin according to any one of the claims 3 to 21 wherein Xa6 is Lys.
23. An analogue of human insulin according to any one of the claims 3 to 21 wherein Xa6 is Thr.
24. An analogue of human insulin according to any one of the claims 3 to 21 wherein Xa6 is Pro.
25. An analogue of human insulin according to any one of the claims 3 to 21 wherein Xa6 is Glu.
26. An analogue of human insulin according to any one of the claims 3 to 25 wherein Xa7 is Thr.
27. An analogue of human insulin according to any one of the claims 3 to 25 wherein Xa7 is Lys.
28. An analogue of human insulin according to any one of the claims 3 to 25 wherein Xa7 is Pro.
29. An analogue of human insulin according to any one of the claims 3 to 25 wherein Xa7 is Glu.
30. An analogue of human insulin according to any one of the claims 3 to 25 wherein Xa7 is -OH.
31. A pharmaceutical preparation comprising i. A derivative of human insulin ii. an analogue of human insulin having a fast onset of action, wherein Phe(B1) is deleted, or Tyr(B26) is replaced with Phe, or Phe(B1) is deleted and Tyr(B26) is replaced with Phe.
32. A pharmaceutical preparation according to claim 31 wherein the ratio of the derivative of human insulin i. to the analogue of human insulin having a fast onset of action ii. is between 1 :99 and 99:1.
33. A pharmaceutical preparation according to claim 32 wherein the ratio is between 10:90 and 90:10.
34. A pharmaceutical preparation according to claim 33 wherein the ratio is between 30:70 and 70:30.
35. A pharmaceutical preparation according to any one of the claims 31 to 34 wherein the derivative of human insulin i. is selected from the group consisting of B29-Nε-myristoyl-des(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε- myristoyl human insulin, B29-Nε-palmitoyl human insulin, B28-Nε-myristoyl Lys828 Pro829 human insulin, B28-Nε-palmitoyl Lys828 Pro829 human insulin, B30-Nε-myristoyl-Thr829Lys830 human insulin, B30-Nε-palmitoyl-Thr829Lys830 human insulin, B29-Nε-(N-palmitoyl-γ-glutamyl)- des(B30) human insulin, B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-N8- (ω-carboxyheptadecanoyI)-des(B30) human insulin and B29-Nε-(ω-carboxyheptadecanoyl) human insulin.
36. A pharmaceutical preparation according to claim 35 wherein the derivative of human insulin i. is B29-N8-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin.
37. A pharmaceutical preparation according to claim 35 wherein the derivative of human in- sulin i. is B29-Nε-myristoyl-des(B30) human insulin.
38. A pharmaceutical preparation according to any one of the claims 31 to 37 wherein the analogue of human insulin ii. is Des(B1) human insulin or Des(B1) Des(B30) human insulin.
39. A pharmaceutical preparation according to claim 38 wherein the analogue of human insulin ii. is Des(B1) human insulin.
40. A pharmaceutical preparation according to any one of the claims 31 to 37 wherein the analogue of human insulin ii. is an analogue according to any one of the claims 1 to 30.
41. A pharmaceutical preparation according to any one of the claims 31 to 40 which further comprises a phenolic preservative.
42. A method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation according to any one of the claims 31 to 41.
43. Use of a preparation according to any one of the claims 31 to 41 for the preparation of a medicament for treatment of type 1 or type 2 diabetes.
EP04738978A 2003-07-11 2004-07-05 Stabilised insulin compositions Withdrawn EP1644411A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301065 2003-07-11
US48768303P 2003-07-16 2003-07-16
PCT/DK2004/000481 WO2005005477A2 (en) 2003-07-11 2004-07-05 Stabilised insulin compositions

Publications (1)

Publication Number Publication Date
EP1644411A2 true EP1644411A2 (en) 2006-04-12

Family

ID=34066438

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04738978A Withdrawn EP1644411A2 (en) 2003-07-11 2004-07-05 Stabilised insulin compositions

Country Status (2)

Country Link
EP (1) EP1644411A2 (en)
WO (1) WO2005005477A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2490243T3 (en) * 2005-02-02 2014-09-03 Novo Nordisk A/S Insulin derivatives
JP4933455B2 (en) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス New insulin derivatives
CN101389650B (en) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5202338B2 (en) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス New insulin derivatives
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
ES2395738T3 (en) * 2006-05-09 2013-02-14 Novo Nordisk A/S Insulin derivative
DE102006031962A1 (en) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CN101541830A (en) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 Protease resistant insulin analogues
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
RU2571857C2 (en) 2008-03-18 2015-12-20 Ново Нордиск А/С Acylated insulin analogues stabilised with respect to proteases
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP6049625B2 (en) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス Treatment of diabetes mellitus using insulin injections given at various injection intervals
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
HUE036702T2 (en) 2013-10-07 2018-07-30 Novo Nordisk As Novel derivative of an insulin analogue
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TWI700091B (en) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JP2003518917A (en) * 1999-05-19 2003-06-17 ゼンコー Novel protein with insulin-like activity useful for the treatment of diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005005477A2 *

Also Published As

Publication number Publication date
WO2005005477A2 (en) 2005-01-20
WO2005005477A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005005477A2 (en) Stabilised insulin compositions
US8263551B2 (en) Soluble, stable insulin-containing formulations with a protamine salt
US20130338071A1 (en) GLP-1 Agonist and Cardiovascular Complications
US20110245163A1 (en) Stabilised Insulin Compositions
US20080280814A1 (en) Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
US20210060132A1 (en) Process for the Preparation of Insulin-Zinc Complexes
JP6755175B2 (en) Insulin medication regimen
US20130261051A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
CN102202683A (en) Treating diabetes melitus using insulin injections with less than daily injection frequency
EP2316446A1 (en) Counteracting drug-induced obesity using GLP-1 agonists
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
WO2007135117A2 (en) Soluble, stable insulin-containing formulations
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US9884094B2 (en) Method of treating diabetes mellitus
WO2007135118A1 (en) Soluble, stable insulin-containing formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060213

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061130